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Mutations in the low-density lipoprotein receptor (LDLR) gene cause familial hypercholesterolemia (FH), a disorder
characterized by coronary heart disease (CHD) at young age. We aimed to apply an extreme sampling method to enhance the
statistical power to identify novel genetic risk variants for CHD in individuals with FH. We selected cases and controls with an
extreme contrast in CHD risk from 17000 FH patients from the Netherlands, whose functional LDLR mutation was
unequivocally established. The genome-wide association (GWA) study was performed on 249 very young FH cases with CHD
and 217 old FH controls without CHD (above 65 years for males and 70 years of age for females) using the Illumina
HumanHap550K chip. In the next stage, two independent samples (one from the Netherlands and one from Italy, Norway,
Spain, and the United Kingdom) of FH patients were used as replication samples. In the initial GWA analysis, we identified 29
independent single nucleotide polymorphisms (SNPs) with suggestive associations with premature CHD (Po1104). We
examined the association of these SNPs with CHD risk in the replication samples. After Bonferroni correction, none of the
SNPs either replicated or reached genome-wide significance after combining the discovery and replication samples. Therefore,
we conclude that the genetics of CHD risk in FH is complex and even applying an ‘extreme genetics’ approach we did not
identify new genetic risk variants. Most likely, this method is not as effective in leveraging effect size as anticipated, and may,
therefore, not lead to significant gains in statistical power.
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INTRODUCTION
Coronary heart disease (CHD) is one of the leading causes of death.1
Multiple genetic risk variants with small to moderate effects on the
susceptibility to CHD have been identified in genome-wide
association (GWA) studies; however, these variants explain only a
small fraction of the heritable component of the risk of CHD.2,3
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Therefore, many genetic variants remain to be discovered. Among the
discovered genes, many are related to lipid metabolism.4,5 New study
designs will be necessary for uncovering additional associated
variants. Selecting the populations who already have high lipid
levels are well suited to search for genes that increase the risk of
CHD beyond dyslipidemia.6 Therefore, we performed a GWA study
in a selected sample of familial hypercholesterolemia (FH) patients
having severe hypercholesterolemia caused by mutations in the low-
density lipoprotein receptor (LDLR) gene (MIM 143890).7
Traditional GWA studies are performed on extremely large sample
sizes including tens of thousands of individuals.8 In contrast, we used an
extreme genetics approach to enhance the statistical power. In this
method, only the individuals with an extreme of the phenotype are
genotyped. In our study, we genotyped FH patients who had CHD at
very young age as cases, and elderly patients who, despite their high low-
density lipoprotein (LDL) cholesterol level, had not experienced CHD as
controls. We hypothesized that using this design would enhance the
identification of additional genetic risk variants of CHD in FH.
MATERIALS AND METHODS
The schematic study design is shown in Figure 1. We performed the study in
two stages. Stage I included a GWA study in the Dutch ‘Association of CHD
Risk in a Genome-wide Old-versus-young Setting’ (ARGOS) sample. Stage II
consisted of genotyping of a second case–control sample, refer to as Mutations
Associated with Risk of Cardiovascular disease in volunteers with Hyper-
cholesterolemia (MARCH) and a large FH cohort, refer to as FH Follow-up
(FHFU). All patients were of Caucasian descent. In ARGOS, this was
confirmed by multi-dimensional scaling of identical-by-state pairwise dis-
tances. All patients gave informed consent and the local ethics committees
approved the protocol.
Description of the populations
Gene-finding stage
ARGOS. The ARGOS sample consists of 500 patients, who were selected
from 17000 Dutch FH patients with a mutation in the LDLR gene. They were
recruited in the Netherlands by the nationwide molecular screening program
of the ‘Stichting Opsporing Erfelijke Familiare Hypercholesterolemie’.9
Phenotypic data (including CHD events) were acquired from general
practitioners and by reviewing medical records at the lipid and cardiologic
clinics. We selected the 264 youngest patients with premature CHD and the
236 oldest patients without any CHD, stratified for sex. The maximum age of
the female cases was 60 years and that of the male cases 45 years. The
minimum age of the controls was 65 years for males and 70 years for females.
First and second degree family members were excluded. CHD was defined as
the presence of at least one of the following: (i) myocardial infarction (MI),
proved by at least two of the following: (a) classical symptoms (415min),
(b) specific abnormalities on electrocardiography, and (c) elevated cardiac
enzymes (42 upper limit of normal); (ii) percutaneous coronary
intervention or other invasive procedures; (iii) coronary artery bypass
grafting (CABG). Patients with angina pectoris were excluded because in the
majority of cases this diagnosis could not be assured by objective data.
MARCH. The MARCH study group consisted of 413 FH patients (190 cases,
223 controls), from Italy, Norway, Spain, and the United Kingdom. A few
patients were born in another country but all were Caucasian. All patients had
clinically proven FH and a mutation in either the LDLR or the APOB gene.
The maximum age of the female cases was 59 and that of the male cases 45
years. The minimum age of the controls was 50 years for males and 60 for
females. For the cases in this cohort, the same CHD definition was applied as
described above for the ARGOS sample with the addition of (iv) angina
pectoris (AP), as this phenotype was accurately addressed in this cohort.
AP was diagnosed as classical symptoms in combination with at least
one unequivocal positive result of one of the following: (a) exercise test,
(b) nuclear scintigram, (c) dobutamine stress ultrasound, or (d) 470%
stenosis on a coronary angiogram. The controls had no manifest CHD.
FHFU study. The second replication cohort consisted of Dutch clinically
proven heterozygous FH patients who were recruited from 27 lipid clinics in
the Netherlands between 1989 and 2002.10,11 For the cases in this cohort, the
same CHD definition was applied as described above for the MARCH sample.
The controls had no manifest CHD. The DNA of 2073 unrelated patients was
available for the present analysis. A total of 51 FH patients had already been
included in the ARGOS sample and were, therefore, removed from the FHFU
group, leaving 2022 DNA samples for analyses.
Additional cohorts. In addition to these three FH cohorts, selected single
nucleotide polymorphisms (SNPs) were also genotyped in population-based
cohorts that have been described in detail previously: The Rotterdam Study
(n¼ 5207, a cohort of elderly inhabitants of a suburb of Rotterdam, from
which we selected patients with prevalent CHD to ascertain that CHD
occurred at relatively young age; 777 CHD cases), deCODE (n¼ 12 848,
selected from the national Islandic deCODE database; 726 cases with
premature MI) and GerMIFSII (n¼ 2520, a German cohort with 1222 proven
MI cases before the age of 60).12–14
Genotyping in ARGOS
The samples of participants of the ARGOS group were assayed with Illumina
Infinium HumanHap550K Chips (Illumina, San Diego, CA, USA) at Erasmus
University Medical Center in Rotterdam, the Netherlands. Samples were
processed according to the Illumina Infinium II manual. In brief, each sample
was whole-genome amplified, fragmented, precipitated, and resuspended in
the appropriate hybridization buffer. After hybridization, these denatured
samples were processed for the single-base extension reaction and were stained
and imaged on an Illumina Bead Array Reader. Normalized bead-intensity data
obtained for each sample were loaded into the Illumina Beadstudio software
where the fluorescent intensities were converted into SNP genotypes. Using
Quanto software (http://biostats.usc.edu/software) considering ARGOS as a
conventional case–control study and assuming large effect sizes owing to only
genotyping the phenotypic extremes, we estimated that had 480% statistical
power to detect effect sizes 42.5 at a genome-wide significant level and than
1.46 for a P-value threshold of 0.05.
Genotyping frequencies have been deposited at the European Genome-
phenome Archive (EGA, http://www.ebi.ac.uk/ega/) which is hosted at the EBI,
under accession number EGAS00001000734. The genotyping data are also
available via the Dutch Biobanking and Biomolecular Research Infrastructure
(https://catalogue.bbmri.nl/biobanks/, accession number 199).
Quality-control filtering
After genome-wide genotyping, a call-rate threshold above 98% was used for
inclusion of the samples. Subjects were excluded from the sample if their sex
was inconsistent with genetic data from the X chromosome and if duplicate
samples produced inconsistent genotypes. SNPs were excluded if they had
ARGOS STAGE I 
249 Youngest FH Patients with CHD 
217 Elderly FH Patients without CHD 
Illumina  550K               29 SNPs p<10-4
MARCH FHFU               STAGE II 
190 Cases 554 Cases 
223 Controls 1 468 Controls 
META-ANALYSIS                 
*MARCH+ FHFU 
*ARGOS + MARCH+ FHFU 
Figure 1 Study design. Abbreviations: CHD, coronary heart disease; FH,
familial hypercholesterolemia; GWA, genome-wide association; SNP, single
nucleotide polymorphism.
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(i) successful genotyping ino90% of the cases and controls, (ii) a minor allele
frequency o1% in the population, (iii) showed deviation from Hardy–
Weinberg equilibrium (P-valueo0.0001), or (iv) were monomorphic across all
samples. After these exclusions, 535 179 SNPs remained.
Genotyping in MARCH and FHFU
In MARCH and FHFU, the genotypes of selected SNPs were determined using
fluorescence-based TaqMan allelic discrimination assays and analyzed on an
ABI Prism 7900 Sequence Detection System (Applied Biosystems, Foster City,
CA, USA). Reaction components and amplification parameters were based on
the manufacturer’s instructions using an annealing temperature of 60 1C.
Results were scored blinded to CHD status. SNPs were excluded following the
same quality criteria as in the gene-finding stage.
Statistical analysis
The genomic inflation factor was calculated using the mean of the w2-tests
generated on all SNPs that were tested. For each SNP which passed the quality
control in the ARGOS population, the association with risk of CHD was
examined in an additive genetic model using a logistic regression model
adjusted for sex. Given the fact that age was an inclusion criterion to generate
the contrast between cases and controls of the ARGOS population, we did not
adjust for age.
We selected all SNPs that were associated with CHD with a P-value
o1.00 104 in ARGOS to analyze in the second stage. In the second stage,
the association with risk of CHD was examined using logistic regression in
MARCH and the FHFU. In MARCH, we adjusted for sex only, as age was a
selection criterion similar to ARGOS. In the FHFU cohort, we adjusted for age,
sex, and statin use, as statin use was expected to be a confounder and, in
contrast to ARGOS and MARCH, it was well documented in that cohort.
Using Bonferroni correction, significance threshold was 0.0017 (0.05/29). We
performed a z-based meta-analysis to combine the results of MARCH and
FHFU in the second stage. Furthermore, we combined the results of all three
studies using z-based meta-analysis.
We used Plink version 1.03 to run GWA study in ARGOS, SPSS version 15
to run logistic regression models in MARCH and FHFU and finally ‘meta’ and
‘rmeta’ packages running under R to perform the meta-analysis.15–17
Replication of well-known SNPs associated with CHD
To test the effect of earlier defined genetic risk variants on CHD in ARGOS, we
analyzed the SNPs described in a large-scale meta-analysis in the CARDIo-
GRAM consortium (22 233 cases and 64 762 controls). Whenever the SNP was
not available on the IlluminaHap550, we used a proxy as identified by SNAP
(http://www.broadinstitute.org/mpg/snap/ldsearchs.php).
RESULTS
Characteristics of the ARGOS cohort
Out of 17 000 Dutch FH patients with a known LDLR mutation, we
selected the 264 youngest FH patients with CHD and the 236 oldest
FH patients without any CHD. The mean±SD (range) age was
41.7±8.3 (23–59 years) in cases and 75.6±5.9 (65–years) in controls.
A total of 249 cases and 217 controls were successfully genotyped.
There were no significant differences in age, smoking, or plasma
cholesterol levels between the patients who were and those who were
not successfully genotyped (data not shown). General characteristics
of the genotyped patients are shown in Table 1 and the age
distribution in Supplementary Figure 1.
Eighty-one cases (32.5%) had a negative LDLR mutation, for
example, a mutation leading to complete loss of function of the
LDL receptor, whereas only 42 controls (19.4%) had a receptor-
negative mutation (P¼ 0.004). This was mainly due to an
overrepresentation of the c.1359-1G4A mutation, which was
present in 46 cases and only in 21 controls. The other mutations
were equally distributed (Supplementary Table 1). On average, the
controls were 34 years older than the cases (P-value o0.001).
Consequently, hypertension and diabetes mellitus were more often
present in the controls than in the cases. More cases than controls
were ever smokers (Table 1).
Stage I (GWA analysis)
After quality-control filtering, we included 535 179 SNPs in the GWA
analysis. A quantile–quantile plot of the observed against expected
P-value distribution is shown in Figure 2. The genomic inflation
factor (lgc) was 1.01 in the total sample. Supplementary Figure 2
illustrates the primary findings from the GWA analysis in the ARGOS
population and presents P-values for each of the interrogated SNPs
across the chromosomes. For a total of 40 SNPs clustered around 21
loci on all chromosomes except 3, 6, 12, 15, 16, and 18–21 the P-value
was lower than the threshold of 1 104 (Table 2). Of these, 11 were
in complete linkage disequilibrium (LD) with a leading SNP in
the same locus. Twelve out of 40 SNPs were located in a cluster on
chromosome 11p15; they were located in four different LD blocks and
could be tagged by six SNPs. We took 29 SNPs, including the 6 SNPs
in11p15, to stage II.
Table 1 Characteristics of the ARGOS population and the replication populations
Diabetes
Population N Males (%) Age (years) Smoking (%) Mellitus (%) Hypertension (%) Total Cholesterol (mmol/l)
Stage I: genome-wide analysis
ARGOS
CHD cases 249 55.0 41.7±8.4a 74.2a 2.4a 19.7a 11.3±2.6a
Controls 217 47.9 75.6±5.9a 51.2a 9.2a 30.0a 10.6±2.8a
Stage II: replication
MARCH
CHD cases 190 63.2 39.4±7.4 49.5b 10.0 36.3 11.0±2.2a
Controls 223 60.1 63.6±9.2 47.1b 11.2 34.5 10.5±1.7a
FHFU
CHD cases 554 65.5a 48.9±10.6a 83.0a 4.8a 16.7a 9.5±2.1
Controls 1468 43.5a 46.6±12.7a 70.3a 1.7a 6.0a 9.4±1.9
Abbreviations: CHD, coronary heart disease; N, number of participants.
Continuous variables are given as mean±SD.
aPo0.05 for the difference between CHD cases and controls within the cohort.
bCases and controls were matched for smoking in the MARCH Study.
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Stage II
We successfully genotyped 28 SNPs in MARCH and all 29 SNPs in
FHFU (Supplementary Table 2). For none of the SNPs, the P-value
was lower than the Bonferroni corrected threshold of 0.017 either in
MARCH or FHFU. The smallest P-value was found for rs176388
(odds ratio OR 0.33, P¼ 0.042) in MARCH. Although the direction
of the effect was the same in FHFU, the association was not significant
(OR 0.80, P¼ 0.36). We performed a meta-analysis to combine the
results of the analysis in MARCH and FHFU. None of the SNPs
reached the Bonferroni significant threshold after combining the
results of MARCH and FHFU.
Finally, we combined the results of ARGOS, MARCH, and FHFU;
however, none of the top SNPs identified in ARGOS reached the
genome-wide significance level. The smallest combined P-value was
4 104 for rs176388, for which the A allele showed a protective
effect in all cohorts. Second best was rs1380945, for which all cohorts
showed that the G allele was associated with increased CHD risk
(Table 3 and Supplementary Figure 3).
Genotyping additional cohorts from the general population did not
show any genome-wide significance.
Replication of well-known SNPs associated with CHD in the
general population
To examine if the genetic risk variants identified in GWA studies in
the general population also showed an effect in ARGOS and to test
whether effect sizes were larger in our ‘extreme genetics’ population,
we examined the association of 25 previously reported genetic risk
factors in CARDIoGRAM. In this meta-analysis, 9 out of 12
previously reported CHD loci were confirmed with a P-value of
o5.0 108 and 13 new ones identified (Table 4).5 None of the
studied SNPs were significantly associated with CHD in ARGOS.
Lowest P-values were obtained for rs4977574 at 9p21
(CARDIoGRAM OR 1.29, 95% CI 1.23–1.36; P¼ 1.35 1022;
Table 2 SNPs influencing coronary heart disease risk in the ARGOS population (with Po1.0104)
SNP Chr Position
Accession
number
Reference
allele
Alternate
allele SNP type Gene
Freq
cases
Freq
controls OR 95% CI P-value
rs12087224 1p22 83 902 972 NT_032977.8 G A Intergenic TTLL7 0.15 0.06 2.54 1.59–4.04 8.86105
rs7581691 2p24 13 953 005 NT_005334.15 G A — — 0.16 0.07 2.62 1.67–4.11 2.93105
rs1406333 2q32 184 155 187 NT_005403.16 A G Intergenic NUP35 0.33 0.47 0.59 0.45–0.77 8.23105
rs2412397 4q12 53 804 380 NT_022853.14 A G Intronic SCFD2 0.31 0.44 0.57 0.43–0.76 9.98105
rs778940 4q13 62 926 680 NT_022778.15 A G Intergenic LPHN3 0.16 0.07 2.44 1.57–3.77 6.74105
rs6835823 4q32 155 191 807 NT_016354.18 A C Intergenic DCHS2 0.48 0.37 1.77 1.36–2.30 2.11105
rs4696207 4q32 155 488 838 NT_016354.18 C A Intronic DCHS2 0.50 0.36 1.80 1.36–2.38 3.36105
rs7691894 4q32 167 900 239 NT_022792.17 A G Intronic SPOCK3 0.39 0.23 2.06 1.53–2.77 1.74106
rs11950716 5p15.2 14 141 834 NT_006576.15 G A Intergenic TRIO 0.14 0.25 0.51 0.36–0.71 9.45105
rs17638888 7q22 98 335 561 NT_007933.14 G A Intronic TRRAP 0.03 0.09 0.27 0.14–0.51 5.89105
rs12544799 8q24.2 130 732 692 NT_008046.15 A G Intergenic MLZE 0.41 0.28 1.87 1.40–2.50 2.53105
rs6985166 8q24.2 130 748 358 NT_008046.15 A G Intergenic MLZE 0.38 0.26 1.81 1.35–2.43 7.81105
rs13291498 9p21 28 326 185 NT_008413.17 A C Intronic LINGO2 0.21 0.33 0.55 0.41–0.73 5.44105
rs10761805 10q21 65 294 147 NT_008583.16 G A Intergenic REEP3 0.49 0.35 1.89 1.42–2.51 1.36105
rs955353 10q21 65 314 593 NT_008583.16 G A — — 0.37 0.50 0.57 0.43–0.75 7.20105
rs2111995 10q25 107 497 352 NT_030059.12 A G Intergenic SORCS3 0.28 0.17 1.97 1.42–2.72 4.10105
rs2647547 11p15 5 359 744 NT_009237.17 A C Intergenic OR51M1 0.46 0.33 1.75 1.33–2.31 5.85105
rs1532514 11p15 5 373 198 NT_009237.17 C A Intergenic OR51M1 0.48 0.38 1.71 1.32–2.23 6.37105
rs10838092 11p15 5 400 443 NT_009237.17 G A Exonic OR51Q1 0.45 0.31 1.73 1.32–2.26 6.73105
rs10838102 11p15 5 414 207 NT_009237.17 G A Intergenic OR51I1 0.46 0.32 1.78 1.36–2.33 3.06105
rs1498486 11p15 5 418 567 NT_009237.17 A C Exonic OR51I1 0.48 0.34 1.81 1.38–2.38 2.02105
rs2133235 11p15 5 423 352 NT_009237.17 C A Intergenic OR51I1 0.44 0.30 1.82 1.28–2.40 2.27105
rs2846186 11q25 134 203 586 NT_033899.7 A G Intergenic B3GAT1 0.18 0.30 0.50 0.36–0.68 1.18105
rs2661969 11q25 134 223 427 NT_033899.7 A G Intergenic B3GAT1 0.18 0.29 0.54 0.39–0.73 9.16105
rs1380945 13q13 31 739 619 NT_024524.13 A G Intronic FRY 0.48 0.35 1.74 1.32–2.30 9.76105
rs4982548 14q11 21 605 911 NT_026437.11 G A Intergenic OR4E2 0.43 0.57 0.56 0.42–0.73 2.43105
rs2531851 17p13 9 141 140 NT_010718.15 G A Intronic STX8 0.40 0.27 1.92 1.43–2.59 1.40105
rs5755595 22q12 33 848 839 NT_011520.11 G A Intergenic RAXLX 0.38 0.26 1.84 1.36–2.48 6.28105
rs5928090 Xp21 32 780 853 NT_011757.15 A G — — 0.42 0.27 1.75 1.18–2.60 4.20105
Abbreviations: CI, confidence interval; Chr, chromosome; Freq, frequency; OR, odds ratio; SNP, single nucleotide polymorphism.
Chromosome base position according to NCBI Genome build 36.3. Intergenic is defined as o500 Mb from the gene.
Figure 2 QQ Plot.
Extreme genetics of CHD in FH
J Versmissen et al
384
European Journal of Human Genetics
ARGOS OR 1.28, 95% CI 1.00–1.67; P¼ 0.05) and for the SNP in the
proprotein convertase subtilisin/kexin type 9 (PCSK9) gene that did
not show genomic signficance in CARDIoGRAM (CARDIoGRAM
OR 1.08, 95% CI 1.05–1.11; P¼ 9.1 108; ARGOS OR 1.52, 95%
CI 1.10–2.12, P¼ 0.01).
DISCUSSION
In this study, by using an extreme genetics approach, we aimed to
fortify our statistical power to identify novel genetic risk variants for
CHD. However, none of the suggestive findings were either confirmed
in the second stage or reached the genome-wide significant threshold
in a meta-analysis of all populations combined.
We expected to identify larger effect sizes in our GWA study,
compared with traditional GWA studies on CHD, for two reasons.
First, we studied genetic risk variants for CHD in a cohort of FH
patients, and hypercholesterolemia is one of the most important risk
factors for CHD. Based on Rothman’s model of causation, one would
expect that in the presence of similar environmental factors, risk
variants in genes will be associated with larger outcome effects.6
Second, we applied an extreme selection approach. Therefore, the
genetic contrast between cases and controls was expected to
increase.18 This incremental contrast has been shown to increase the
power in simulation studies in quantitative traits. The effect sizes
found when selectively genotyping only the phenotypic extremes will
be increased.18–20 Plomin suggested that common disorders could
also be considered as quantitative traits, as risk on a common disease
in the population could be regarded as a distribution of ‘polygenetic
liability’ to a disease. The extreme sampling approach should,
therefore, produce larger effect sizes in our study as well. Thus, the
power was expected to be relatively high, despite the reduction in
number of individuals as a result of the selection criteria.18,19,21 Our
study is the first to apply this method using real data. Using Quanto,
we confirmed that the study was sufficiently powered to identify risk
variants with large effect sizes in this high-risk group of subjects. Our
findings, being more specific our odds ratios, indicate that the
leverage in effect size using this approach is, in fact, quite modest.
This is also clear from the data from CARDIoGRAM in our study, as
an example, the well-replicated locus at 9p21.3 had an OR of 1.28,
very close to the 1.25 value that was found in the original study of
subjects from the general population. Most other known CHD risk
SNPs identified in earlier studies and published by Schunkert et al5
were not associated with statistically significant effects in this FH
sample. However, our study was underpowered for this analysis if the
true effect sizes were the same as reported and less increased by our
design than anticipated, so we can only look at the direction of the
effect. Out of 18 SNPs that could be tested, 11 ORs were in the same
direction, whereas only 6 were not (Table 4). Of these 11, most
interesting was the SNP in PCSK9. This SNP is associated with an
8% higher risk of CHD in the general population; however, the odds
in ARGOS were increased by 450%. Although the P-value in
Table 3 Results of the genome-wide association study in the two FH replication populations
MARCH (n¼413) FHFU (N¼2022) Meta-analysis MARCHþFHFU Meta-analysis ARGOSþMARCH þFHFU
SNP Risk allele OR P-value OR P-value OR P-value OR P-value
rs12087224 A 1.01 0.96 1.06 0.70 1.04 0.73 1.27 3.1102
rs7581691 A 1.07 0.79 0.86 0.35 0.91 0.51 1.20 1.2101
rs1406333 G 0.98 0.89 0.96 0.71 0.98 0.68 0.84 1.5102
rs2412397 G NA NA 0.91 0.36 NA NA NA NA
rs778940 G 0.86 0.53 1.29 0.06 1.16 0.17 1.35 2.9103
rs6835823 C 1.07 0.63 0.94 0.66 1.01 0.93 1.24 8.4103
rs4696207 A 0.90 0.48 1.10 0.33 1.03 0.70 1.19 1.4102
rs7691894 G 1.02 0.99 1.03 0.74 1.02 0.80 1.20 1.2102
rs11950716 A 0.83 0.35 0.94 0.60 0.91 0.34 0.78 5.8103
rs17638888 A 0.52 0.04 0.80 0.36 0.69 0.05 0.54 2.0104
rs12544799 G 1.06 0.70 0.94 0.52 0.98 0.77 1.14 7.6102
rs6985166 G 1.05 0.76 1.09 0.38 1.08 0.36 1.22 6.4103
rs13291498 C 0.92 0.62 1.22 0.06 1.12 0.21 0.92 2.9101
rs10761805 A 1.05 0.76 1.00 0.99 1.01 0.87 1.18 2.2102
rs955353 A 0.88 0.36 1.01 0.91 0.97 0.67 0.85 1.9102
rs2111995 G 0.81 0.22 1.14 0.23 1.03 0.74 1.20 2.3102
rs2647547 C 0.98 0.90 1.04 0.67 1.02 0.79 1.17 2.4102
rs1532514 A 1.04 0.79 1.01 0.88 1.02 0.81 1.16 2.6102
rs10838092 A 1.09 0.59 1.00 0.96 1.02 0.80 1.18 2.4102
rs10838102 A 1.20 0.21 0.96 0.70 1.03 0.71 1.19 1.5102
rs1498486 C 1.11 0.45 1.07 0.51 1.08 0.34 1.23 3.1103
rs2133235 A 1.20 0.22 1.93 0.48 1.01 0.93 1.17 2.5102
rs2846186 G 0.83 0.26 1.06 0.63 0.97 0.76 0.81 1.1102
rs2661969 G 0.83 0.23 0.97 0.97 0.91 0.35 0.79 4.9103
rs1380945 G 1.25 0.13 1.14 0.19 1.17 0.06 1.29 3.0104
rs4982548 A 1.02 0.89 1.07 0.45 1.05 0.48 0.91 1.7101
rs2531851 A 1.07 0.63 0.89 0.23 0.95 0.51 1.11 1.4101
rs5755595 A 0.80 0.15 0.90 0.33 0.86 0.10 1.05 5.4101
rs5928090 G 1.04 0.73 0.95 0.54 0.98 0.73 1.08 2.3101
Abbreviation: OR, odds ratio.
Combined P-value given for replication populations.
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CARDIoGRAM did not reach genome-wide significance, it is tempting
to speculate that this finding and the enhanced effect in ARGOS is not
due to chance, but might reflect an interaction between this gene and
cholesterol levels. PCSK9 is a gene encoding proprotein convertase
subtilisin/kexin type 9, involved in the intracellular degradation of LDL
receptors. PCSK9 levels correlated inversely with LDL cholesterol levels
in FH patients.22 PCSK9 inhibitors are being tested in phase III trials23
now, and are expected to be highly effective in FH patients.24,25
Our definition of extreme groups might have been too
restrictive, as it constitutes a very small proportion of the FH sample
(500 out of 17 000).
Nevertheless, our findings may help to understand why genetic risk
prediction models have not yet succeeded. In our approach, we
attempted to identify novel genes by selecting the extreme groups of
the CHD risk distribution spectrum. Genetic risk prediction studies,
on the other hand, start with genetic information and estimate who
will end up in the low- and the high-risk group.26 As we could
demonstrate that the effect sizes in this design are not as enlarged as
we expected, the contrast needed for prediction might be less than
anticipated as well: genetic risk factors most likely have a more
gradual distribution over the population instead of being over- or
underrepresented in the phenotypic extremes and the combination of
classical and genetic risk factors defines the CHD risk.
Our approach has a number of limitations. Finding extreme cases is
a challenging effort. Although FH is a relatively common genetic
disorder, collecting a large sample of subjects either with early onset
CHD or healthy aging is difficult. The low genomic inflation factor
(1.01) in the total sample indicated that population admixture was
not likely.27 We do realize that from a statistical point of view our
sample size was not enough to detect genes with small effects.
Another issue might be whether difference in age between cases and
controls might bring in extra confounding. Although only Caucasian
patients were studied, first and second degree family members were
excluded and we had phenotypic data, we cannot exclude the presence
of an unknown confounder. A last limitation of a GWA study in FH
subjects is that the results may not necessarily apply to the general
population.28 Results may be restricted to FH patients or to
hypercholesterolemic patients in general. Also, it might be possible
that CHD risk in the young is genetically different from CHD risk at
an older age.
We conclude that the genetics of CHD risk in FH is complex and
even applying an ‘extreme genetics’ approach, we did not identify new
genetic risk variants. Most likely, this method is not as effective in
leveraging effect size as anticipated, and may, therefore, not lead to
significant gains in statistical power. Also, this study might explain
why genetic risk prediction modeling is yielding disappointment.
The odds ratio associated with genetic variation at the PCSK9 locus
points to important consequences for PCSK9 activity in FH patients
and provides hope for the novel approach to lower these levels
through monoclonal antibodies in order to prevent CHD.
Table 4 Results of earlier identified genetic risk factors in ARGOS5
CARDIoGRAM
SNP Chr
Gene(s) in
region
Accession
number
Ref.
allele
Risk allele
(frequency) OR P-value Genotyped Proxya ORb P-value
rs11206510 1p32.3 PCSK9 NT_032977.9 C T (0.82) 1.08 9.1108 Yes 1.52 0.01
rs17114036c 1p32.2 PPAP2B NT_039277.8 G A (0.91) 1.17 2.2106 No rs9970807 0.87 0.56
rs599839 1p13.3 SORT1 NT_019273.18 G A (0.78) 1.11 2.91010 No rs646776 1.00 0.99
rs17465637 1q41 MIA3 NT_021877.18 A C (0.74) 1.14 1.4108 No No proxy
rs6725887 2q33.1 WDR12 NT_005403.16 T C (0.15) 1.14 1.1109 Yes 1.07 0.76
rs2306374 3q22.3 MRAS NT_005612.15 T C (0.18) 1.12 3.3108 Yes 0.96 0.81
rs12526453 6p24.1 PHACTR1 NT_007592.14 G C (0.67) 1.10 1.2109 No rs4714990 1.03 0.8
rs17609940c 6p21.31 ANKS1A NT_007592.14 C G (0.75) 1.07 2.2106 No rs820082 0.83 0.25
rs12190287c 6q23.2 TCF21 NT_025741.14 G C (0.62) 1.08 4.61011 No No proxy
rs3798220 6q25.3 LPA NT_007422.13 T C(0.02) 1.09 3.01011 No No LD data
rs11556924c 7q32.2 ZC3HC1 NT_007933.14 T C (0.62) 1.09 2.2109 No No proxy
rs4977574 9p21.3 CDKN2A, CDKN2B NT_008413.17 A G (0.46) 1.25 1.41022 Yes 1.28 0.05
rs579459c 9q34.2 ABO NT_035014.4 T C (0.21) 1.10 1.2107 No rs495828 1.35 0.08
rs1746048 10q11.21 CXCL12 NT_033985.6 T C (0.87) 1.33 2.91010 Yes 1.41 0.1
rs12413409c 10q24.32 CYP17A1, CNNM2, NT5C2 NT_030059.12 A G (0.89) 1.12 1.5106 Yes 1.23 0.36
rs964184c 11q23.3 ZNF259, APOA5-A4-C3-A1 NT_03899.8 C G (0.13) 1.13 8.01010 No No proxy
rs3184504 12q24.12 SH2B3 NT_033899.7 C T (0.44) 1.13 6.4106 Yes 1.01 0.96
rs4773144c 13q34 COL4A1, COL4A2 NT_009952.14 A G (0.44) 1.07 4.2107 No No proxy
rs2895811c 14q32.2 HHIPL1 NT_026437.11 T C (0.43) 1.07 2.7107 Yes 1.05 0.72
rs3825807c 15q25.1 ADAMTS7 NT_01094.16 G A (0.57) 1.08 9.6106 No rs7177699 NA NA
rs216172c 17p13.3 SMG6, SRR NT_010718.15 G C (0.37) 1.07 6.2107 No rs2281727 0.85 0.26
rs12936587c 17p11.2 RASD1, SMCR3, PEMT NT_010718.15 A G (0.56) 1.07 4.9107 No rs11871738 0.83 0.14
rs46522c 17q21.32 UBE2Z, GIP, ATP5G1, SNF8 NT_010783.14 C T (0.53) 1.06 3.6106 No rs962272 1.04 0.73
rs1122608 19p13.2 LDLR NT_011295.10 T G (0.77) 1.14 9.71010 No rs3786725 0.81 0.17
rs9982601 21q22.11 MRPS6 NT_011512.10 C T (0.15) 1.18 4.21010 No rs7278204 1.28 0.19
Abbreviation: Ref., reference.
Chromosome position according to NCBI Genome build 36.3.
aUsing SNAP (http://www.broadinstitute.org/mpg/snap/ldsearchs.php).
bRisk allele or representative proxy.
cOR representing combined analysis CARDIoGRAM & replication cohort.5
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